Proparacaine

Generic Name: Proparacaine

Brand Names: Alcaine, Lenalidomide Krka d.d. Novo mesto (previously Lenalidomide Krka), Revlimid, Lenalidomide Mylan, Lenalidomide Krka (previously Lenalidomide Krka d.d. Novo mesto), Lenalidomide Accord

Drug Type: Small Molecule

Chemical Formula: C_₁₆H_₂₆N_₂O_₃

CAS Number: 499-67-2

Unique Ingredient Identifier: B4OB0JHI1X

Background: Proparacaine is a topical anesthetic drug of the amino ester group. It is found in ophthalmic solutions at a concentration of 0.5% as the hydrochloride salt.

Indication: Used as a local (ophthalmic) anesthetic.

Associated Conditions: Chronic Lymphocytic Leukemia (CLL) - Refractory, Follicular Lymphoma ( FL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), Multiple Myeloma (MM), Myelodysplastic Syndrome, Primary Amyloidosis, Refractory Diffuse Large B Cell Lymphoma (DLBCL)

Associated Therapies: Local Anaesthesia therapy

Clinical Trials

A Study of Glofitamab and Lenalidomide in People With Mantle Cell Lymphoma

Phase 1

Recruiting

Conditions: Mantle Cell Lymphoma
MCL

Interventions: Drug: Glofitamab
Drug: Obinutuzumab
Drug: Lenalidomide

First Posted Date: 2024-01-05

Last Posted Date: 2025-05-21

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 39

Registration Number: NCT06192888

Locations: 🇺🇸
Dana Farber Cancer Institute (Data Collection and Specimen Analysis), Boston, Massachusetts, United States
🇺🇸
Mayo Clinic (Data Collection Only), Rochester, Minnesota, United States
🇺🇸
Washington University (Data Collection Only), Saint Louis, Missouri, United States

and more 7 locations

FeAsiBility of a Treatment Free Interval in Newly Diagnosed MM Patients Treated With Daratumumab-lenalidomide-dexamethasone (HOVON174MM)

Phase 3

Recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Daratumumab Injection
Drug: Dexamethasone
Drug: Lenalidomide capsule

First Posted Date: 2024-01-02

Last Posted Date: 2024-08-19

Lead Sponsor: Stichting Hemato-Oncologie voor Volwassenen Nederland

Target Recruit Count: 599

Registration Number: NCT06187441

Locations: 🇳🇱
NL-Amsterdam- UMC, Amsterdam, Netherlands
🇳🇱
NL-Amsterdam-AmsterdamUMC, Amsterdam, Netherlands
🇳🇱
Nij Smellinghe Ziekenhuis, Drachten, Netherlands

and more 35 locations

Fixed Duration vs Continuous Daratumumab in Transplant Ineligible Older Adults With Newly Diagnosed Multiple Myeloma

Phase 3

Recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Lenalidomide
Drug: Daratumumab
Drug: Dexamethasone

First Posted Date: 2023-12-27

Last Posted Date: 2025-05-13

Lead Sponsor: Canadian Cancer Trials Group

Target Recruit Count: 559

Registration Number: NCT06182774

Locations: 🇨🇦
Dr. H. Bliss Murphy Cancer Centre, St. John's, Newfoundland and Labrador, Canada
🇨🇦
CHU de Quebec-Hopital l'Enfant-Jesus (HEJ), Quebec City, Quebec, Canada
🇨🇦
BCCA - Kelowna, Kelowna, British Columbia, Canada

and more 21 locations

Pola-R2 in Newly Diagnosed Non-fit Elderly DLBCL Patients

Phase 2

Recruiting

Conditions: Diffuse Large B Cell Lymphoma

Interventions: Drug: Polatuzumab Vedotin, Rituximab, Lenalidomide

First Posted Date: 2023-12-20

Last Posted Date: 2023-12-20

Lead Sponsor: Yan Zhang, MD

Target Recruit Count: 30

Registration Number: NCT06176729

Locations: 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China

MCLENA-2: A Phase II Clinical Trial for the Assessment of Lenalidomide in Patients With Mild Cognitive Impairment

Phase 2

Not yet recruiting

Conditions: Cognitive Impairment, Mild
Cognitive Dysfunction
Amyloid Plaque
Neurodegenerative Disease, Hereditary
Inflammation, Brain

Interventions: Drug: Lenalidomide 10 mg

First Posted Date: 2023-12-20

Last Posted Date: 2025-05-18

Lead Sponsor: St. Joseph's Hospital and Medical Center, Phoenix

Target Recruit Count: 45

Registration Number: NCT06177028

Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma

Phase 2

Recruiting

Conditions: Multiple Myeloma

Interventions: Procedure: Biospecimen Collection
Procedure: Bone Marrow Aspiration
Procedure: Bone Marrow Biopsy
Drug: Bortezomib
Procedure: Computed Tomography
Biological: Daratumumab
Drug: Daratumumab and Recombinant Human Hyaluronidase
Drug: Dexamethasone
Procedure: Magnetic Resonance Imaging
Drug: Lenalidomide
Procedure: Positron Emission Tomography
Drug: Selinexor

First Posted Date: 2023-12-13

Last Posted Date: 2025-03-14

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 70

Registration Number: NCT06169215

Locations: 🇺🇸
UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine, California, United States
🇺🇸
UCI Health Laguna Hills, Laguna Hills, California, United States
🇺🇸
UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California, United States

and more 24 locations

Lenalidomide Combined With G-CHOP in the Treatment of Newly Diagnosed DLBCL With FL

Phase 2

Recruiting

Conditions: Follicular Lymphoma
DLBCL - Diffuse Large B Cell Lymphoma

Interventions: Drug: Lenalidomide combined with G-CHOP (LO CHOP)

First Posted Date: 2023-11-30

Last Posted Date: 2025-02-19

Lead Sponsor: The First Affiliated Hospital of Xiamen University

Target Recruit Count: 38

Registration Number: NCT06151080

Locations: 🇨🇳
Bing Xu, Xiamen, Fujian, China

A Trial to Learn if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma

Phase 3

Recruiting

Conditions: Marginal Zone Lymphoma (MZL)
Relapsed/Refractory Follicular Lymphoma

Interventions: Drug: Odronextamab
Drug: Lenalidomide
Drug: Rituximab

First Posted Date: 2023-11-28

Last Posted Date: 2025-05-13

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 470

Registration Number: NCT06149286

Locations: 🇦🇹
Klinikum Wels Grieskirchen, Wels, Austria
🇧🇪
Institut Jules Bordet, Brussels, Belgium
🇺🇸
David Geffen School of Medicine at UCLA, Los Angeles, California, United States

and more 139 locations

Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma

Phase 2

Recruiting

Conditions: Multiple Myeloma
Extramedullary Multiple Myeloma
Primary Plasma Cell Leukemia

Interventions: Drug: Daratumumab
Drug: Carfilzomib
Drug: Lenalidomide
Drug: Dexamethasone
Drug: Cisplatin
Drug: epirubicin
Drug: Cyclophosphamide
Drug: Etoposide
Drug: Melphalan
Procedure: ASCT
Drug: bortezomib

First Posted Date: 2023-11-21

Last Posted Date: 2025-04-16

Lead Sponsor: Wuhan Union Hospital, China

Target Recruit Count: 54

Registration Number: NCT06140966

Locations: 🇨🇳
Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China

Lenalidomide and Epcoritamab for the Treatment of Previously Untreated Follicular Lymphoma

Phase 2

Recruiting

Conditions: Follicular Lymphoma

Interventions: Procedure: Biospecimen Collection
Procedure: Bone Marrow Biopsy
Procedure: Computed Tomography
Other: Electronic Health Record Review
Biological: Epcoritamab
Drug: Lenalidomide
Procedure: Magnetic Resonance Imaging
Procedure: Positron Emission Tomography

First Posted Date: 2023-11-02

Last Posted Date: 2025-05-01

Lead Sponsor: City of Hope Medical Center

Target Recruit Count: 27

Registration Number: NCT06112847

Locations: 🇺🇸
City of Hope Medical Center, Duarte, California, United States
🇺🇸
City of Hope at Irvine Lennar, Irvine, California, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy